No Image 01Jun

by

INTERVIEW: Oscotec Lays Out Global Ambitions For RA, Cancer Drugs

No Image 01Jun

by

Oscotec wins exception policy for continued R&D for new drugs

No Image 03Mar

by

Oscotec and Beactica Therapeutics announce license and collaboration agreement to develop new cancer drug

No Image 03Mar

by

Other news to note for March 2, 2021

No Image 15Sep

by

Oscotec/ADEL Announce FDA Clearance of IND Application of ADEL-Y01 for the Treatment of Alzheimer's Disease

No Image 27Feb

by

Oscotec/ADEL Initiates First-in-Human Dosing in Ph1 of Anti-MTBR Tau Antibody ADEL-Y01 In Alzheimer's Disease

No Image 01Jun

by

G-749, a novel FLT3 Kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia.

No Image 01Jun

by

Oscotec shares rebound on launch of US clinical trial

No Image 01Jun

by

Oscotec`s acute leukemia treatment wins orphan drug status from FDA

No Image 01Jun

by

Abstract 2010 : SKI-G-801, an AXL kinase inhibitor, blocks metastasis and induces anti-tumor immune response in various syngeneic cancer models

No Image 01Jun

by

AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications

No Image 01Jun

by

Oscotec`s SYK inhibitor Program Gets Korea Drug Fund Money